-
Two very recent publications address the management of newly diagnosed multiple myeloma. In the first, two bortezomib-containing three-drug regimens proved equally effective as a more complex four-drug regimen in achieving meaningful initial responses. The second demonstrated the value of maintenance lenalidomide for achieving longer progression-free survival.
-
The patient is a 56-year-old woman with known meningioma first resected in 1999 followed by external beam irradiation. In 2005, she developed progressive right leg weakness and had a second operation and course of radiation.
-
The practice of tanning by artificial means, such as by sunlamps or sunbeds, continues to be popular, particularly in young people despite the acknowledged risk for increased skin cancer.
-
Drug shortages; metformin and cancer prevention; migraine prevention guidelines; and FDA actions.
-
-
Ipilimumab has recently been approved for the treatment of advanced melanoma. The current trial was undertaken to determine its safety and efficacy in patients with brain involvement.
-
Preclinical studies provide a rationale for examining a role for sunitinib in the treatment of breast cancer. However, in this large, multicenter trial, the combination of sunitinib with docetaxel did not prolong progression-free or overall survival when compared to docetaxel alone, and it appeared to be less well tolerated. The role for sunitinib remains to be established for the treatment of breast cancer.
-
Side effects of statins; effects of cannabis use; antihypertensives and lip cancer; and FDA actions.
-
-
There has been much written about the salutary effects of moderate alcohol consumption in reference to a number of non-malignant chronic diseases. The effects on cancer in general are less compelling. However, in the current meta-analysis examining alcohol consumption and the development of renal cell carcinoma, a protective effect for light and moderate drinkers is clearly demonstrated. This protective effect is in the 10-20% range.